Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Book Review
Book Reviews
Classics In Indian Medicine
Clinical Case Report
Clinical Case Reports
Clinical Research Methods
Clinico-pathological Conference
Eminent Indians in Medicine
Everyday Practice
Film Review
History of Medicine
Images In Medicine
Indian Medical Institutions
Letter from Bristol
Letter from Chennai
Letter From Ganiyari
Letter from Glasgow
Letter from London
Letter From Mumbai
Letter From Nepal
Medical Education
Medical Ethics
Medicine and Society
News From Here And There
Original Article
Original Articles
Review Article
Selected Summaries
Selected Summary
Short Report
Short Reports
Speaking for Myself
Speaking for Ourselve
Speaking for Ourselves
View/Download PDF

Translate this page into:

PMID: 28098095


Vivek Arya

Corresponding Author:
How to cite this article:
Arya V. Masala. Natl Med J India 2016;29:315-316
Copyright: (C)2016 The National Medical Journal of India

The rich do live longer!

A group of economists assessed the relationship between income and life expectancy in the USA. Data on income were obtained from 1.4 billion de-identified tax records between 1999 and 2014 and mortality data from Social Security Administration death records. These data were used to estimate life expectancy at 40 years of age. The sample consisted of 1 408 287 218 person-year observations for individuals aged 40 to 76 years with a mean age of 53 years and median household earnings of $61 175 per year. Higher income was associated with greater longevity throughout the income distribution. There was a gap of 14.6 years in life expectancy between the richest 1% and poorest 1% of individuals for men and 10.1 years for women. Over time the rise in life expectancy was much greater for the rich as compared to the poor. Between 2001 and 2014, life expectancy increased by 2.34 years for men and 2.91 years for women in the top 5% of the income distribution, but by only 0.32 years for men and 0.04 years for women in the bottom 5% (JAMA 2016. Published online 10 Apr 2016. doi:10.1001/jama.2016.4226).

From the frying pan … into the fire!

From Brigham and Women′s Hospital, Boston comes this intriguing report of the hazards of indiscriminately using stem cells. The authors report the case of a 66-year-old man who underwent intrathecal infusions of stem cells in Argentina, Mexico and China for the treatment of residual deficit from an ischaemic stroke. He then developed progressive lower back pain, paraplegia and urinary incontinence. Imaging revealed a lesion of the thoracic spinal cord and thecal sac; a biopsy showed a densely cellular, highly proliferative, primitive neoplasm with glial differentiation. DNA fingerprinting revealed that the cells in this tumour were not host cells and were likely to have originated from the infused stem cells. The tumour could not be categorized as one of the known glial neoplasms. The authors caution against the tumorigenic potential of stem cells (N Engl J Med 2016; 375: 196-8).

Cancer did not spare even pre-historic man

Recent findings from a hominin metatarsal specimen found in South Africa challenge the assumption that the increased incidence of malignancies is the result of a polluted environment and lifestyle changes. At Swartkrans, 40 km northwest of Johannesburg, hominin specimens were found in caves; of these, SK 7923 is a fifth metatarsal from a primitive ancestor. This specimen has a hemispherical bony mass located on the shaft, abutting the cortical bone surface. A team of researchers from Johannesburg had initially diagnosed this lesion to be an osteoid osteoma. However, they re-analysed the specimen by using micro focus X-ray computed tomography. This revealed evidence of remodelling and bone formation. Findings were very similar to those in a recently diagnosed osteosarcoma of the femur. The authors concluded that the specimen represented the earliest reported case of malignancy in pre-historic man (S Afr J Sci 2016; 112: 2015-0471,

Cardiovascular outcomes with newer oral anti-diabetic drugs

To assess the outcomes of treatment in patients with type 2 diabetes mellitus, researchers studied data from 469 688 patients from 1243 general practices in the UK registered in the Qresearch database. Exposure was defined as the drug therapy received by these patients and outcomes included cardiovascular disease, heart failure and all-cause mortality. Of newer anti-diabetes drugs, users of gliptins had an 18% decreased risk of all-cause mortality and a 14% reduced risk of heart failure compared with patients who did not use these drugs. Similarly, glitazone use was associated with a 23% reduction in all-cause mortality, 26% decreased risk of heart failure and a 25% reduced risk of cardiovascular disease (BMJ 2016; 354: i3477).

Pioglitazone use and the risk of bladder cancer

Pioglitazone is an insulin-sensitizing drug used in the treatment of type 2 diabetes. Concerns have been raised regarding an increase in the risk of carcinoma of the urinary bladder with its use; hence the drug was briefly banned in India in 2015. Researchers analysed retrospective data from patient databases in Sweden, Finland, the Netherlands and UK, which included 56 337 patients with type 2 diabetes who had been given pioglitazone and 317 109 matched patients who were given other drugs for their diabetes. After a mean follow-up of 2.9 years, 130 urinary bladder cancers occurred in the pioglitazone-treated group and 153 in the matched cohort (hazard ratio for bladder cancer 0.99). There was no increased risk of bladder cancer with higher cumulative doses or duration of treatment with pioglitazone (BMJ 2016; 354: i3903).

The mystery of Shackleton′s heart

Between 1901 and 1922, Sir Ernest Shackleton undertook four voyages to explore Antarctica. On three of these expeditions, he suffered physical breakdowns. Much speculation has gone into the cause for his failing health. Researchers from the Royal Brompton Hospital, London, analysed diary entries made by Dr Eric Marshall, the medical officer on Shackleton′s second expedition to the Antarctic (1907-9) in the Nimrod. The diary entries describe Shackleton as being exhausted with heavy work, the finding of tachycardia with an irregular pulse and the auscultation by Dr Marshall of a pulmonary systolic murmur. The authors concluded that the cardiac disease was possibly atrial septal defect with an arrhythmia and that Shackleton was aware of this, avoiding medical evaluation for fear of being prevented from going on his expeditions. The cause of his premature death at the age of 47 remains unclear but could have been related to his congenital heart disease or to atherosclerosis since he was a heavy smoker (J Royal Soc Med 2016; 109: 106-8).

Fulltext Views

PDF downloads
Show Sections